Evaluating the impact of RSV immunisation strategies on antibiotic use in England

Katherine E. Atkins, David Hodgson, Mark Jit, Nicholas G. Davies

Corresponding author. Address for correspondence: Katherine E. Atkins, Centre for Global

Health, Usher Institute, MacKenzie House

30 West Richmond Street, University of Edinburgh, EH8 9DX, United Kingdom. E-mail:

katherine.atkins@ed.ac.uk

Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (K.E.

Atkins, D. Hodgson, N.G. Davies); University of Edinburgh, Scotland, UK (K.E. Atkins).

12
13

Abstract

With a sizable fraction of primary care antibiotics prescribing attributable to RSV, the promising suite of prophylactic pharmaceuticals against could reduce the need for antibiotics in addition to controlling respiratory disease. To assess the potential impact of RSV vaccines on the reduction in primary care antibiotic prescribing in England, we integrate results from a dynamic transmission model of RSV and a statistical attribution framework. Under base case assumptions, targeting children aged 5-14 years reduces antibiotic prescribing by 10.9 (8.0-14.2) antibiotic courses per 10,000 person years. This reduction in antibiotic use would gain 128 DALYs and avert 51,000 GBP associated with infections caused by drug resistant bacteria. Seasonally administering monoclonal antibodies (mAbs) to high risk infants under 6 months is the most efficient strategy (reducing per person year antibiotic prescribing by 2.6 (1.9-3.3) antibiotic courses per 1,000 mAb courses).

Introduction

Vaccines against viral pathogens have been suggested as a novel means to reduce antibiotic resistance (1). By reducing the number of viral infections, fewer antibiotics would be used either inappropriately against viral disease, as a precautionary measure for non-specific symptoms, or to treat bacterial co-infections (2,3). Consequently, this reduction in antibiotic use would exert less selection for resistance on highly prevalent commensal bacteria that can lead to invasive disease.

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infections in young children globally (4). RSV can cause mild upper respiratory tract symptoms across all age groups and these infections can often result in primary care visits (5). Data from high income countries suggest that antibiotic prescribing is common amongst primary care visits attributable to RSV infection, and consequently, reducing RSV infections may be beneficial to control antibiotic resistance across highly prevalent bacterial species (6,7). Currently there are seven RSV vaccine formulations in Phase III clinical trials, including those targeting children, pregnant women, and the elderly (8). However, there are currently no estimates of the potential impact of RSV vaccines on preventing either antibiotic prescribing or antibiotic resistance.

In this study we evaluate the likely impact of the new generation of RSV vaccine strategies on antibiotic prescribing in England, a high income setting, and use these predictions to quantify the reduction in antibiotic resistance outcomes.

Methods

Literature review

We searched Pubmed using the terms: ("Respiratory Syncytial Virus, Human"[MeSH Terms]

OR "Respiratory Syncytial Virus Infections"[MeSH Terms]) AND ("antibiotic" OR "antibiotics"

OR "antimicrobial" OR "antimicrobials") up to 3 November 2021. We included all those studies

that evaluated the impact of an RSV vaccine on antibiotic use, or that estimated antibiotic use in

the community, outpatient or long term care facility settings that was either i) coincident with

respiratory infection symptoms with virologically confirmed RSV infection, or ii) attributed to

RSV via statistical methods. We excluded all studies that reported antibiotic use only in

hospitalised individuals or those attending emergency care, and excluded all review and

commentary articles. We included patients of all ages and in any risk group.

Vaccine strategies

We evaluated the impact of 12 potential RSV immunisation strategies on antibiotic prescribing

rates in England. Specifically, we predicted the impact of a suite of vaccine strategies relying on

vaccines that are currently under evaluation in clinical trials that can be administered via age

groups or risk groups feasibly and affordably (9,10). These strategies are: vaccination of infants

at two months (seasonally - VAC INF S, or year round - VAC INF A); vaccination during the

third trimester of pregnancy (seasonally - MAT S, or year-round - MAT A); seasonal vaccination

of toddlers aged 2-4 years (VAC 2-4 S), primary school children aged 5-9 years (VAC 5-9 S) or

primary and secondary school children aged 5-14 years (VAC 5-14 S); and, seasonal

administration of long-acting monoclonal antibodies. These monoclonal antibody strategies are,

in increasing order of number of doses given: very high risk infants under 8 months currently

eligible for Palivizumab (MAB VHR S) (11), high risk infants at birth as well as those currently

eligible for Palivizumab (MAB HR S), high risk infants under 6 months as well as those

currently eligible for Palivizumab (MAB HR S+), all infants at birth (MAB ALL S), or all

infants under 6 months (MAB ALL S+).

We considered the efficacy against infection of long acting monoclonal antibodies and of

maternal vaccination to be consistent with respective clinical trials, but that vaccine efficacy

against infection in infants, toddlers and older children is consistent with natural infection, in the

absence of clinical trial data (9) (**Table 2**). We assumed that vaccine uptake was consistent with

other vaccine strategies delivered to the same age groups, and the monoclonal antibody uptake

was the same as that for Palivizumab (9). We assumed that all vaccine strategies were

administered in addition to Palivizumab while all monoclonal antibody strategies replaced

Palivizumab.

Antibiotic courses averted

We first calculated the age-specific reduction in the number of antibiotic courses per 1000 person

years due to each of these 12 vaccine strategies by multiplying the age-specific fraction of

primary case visits averted with the age-specific number of primary care visits attributable to

RSV that result in an antibiotic prescription.

i) Primary case visits averted: We calculated the average proportional reduction in primary care

visits for 0-5 months, 6-23 months, 2-4 years, 5-17 years, 18+ years using a dynamic

transmission model for RSV in England (9). We calculated the average reduction across a ten

year time horizon after implementation of each immunisation strategy relative to the current

status quo, Palivizumab administered seasonally to very high risk infants (9). For each

intervention, we generated 1,000 estimates that captured uncertainty in the RSV incidence and

the intervention impact via the joint posterior model parameter distribution using the efficacy

and uptake parameter estimates (**Table 2**).

ii) RSV-attributable primary care antibiotic prescribing: In our base case analysis, we used

estimates from a previous statistical attribution model that calculated the prescribing rates in

primary care attributable to RSV in England and Wales (calculated as the number of antibiotic

courses per 100,000 person years for the age groups 0-5mo. 6-23mo, 2-4y and 5-17y) (6). For

each of the five age groups, we assumed the point value and confidence intervals to be from a

triangular distribution with a mode and 95% confidence intervals, respectively and generated

1,000 samples from these distributions (**Table 3**).

We performed sensitivity analyses on the RSV-attributable antibiotic prescribing. Specifically,

we used an alternative study from Scotland that calculated both the total primary care

prescriptions and the fraction of these prescriptions attributable to RSV for infants for 0-11mo

and for 1-4yr (7) (**Table 3**). To calculate the proportion of RSV-attributable prescriptions for 5-

17y we assumed that the ratio of prescribing for those aged 5-17y to those aged 2-4y was the

same as the base case study. In the first sensitivity analysis we assumed that the antibiotic

prescribing rate in those aged 18+y was the same as that for those aged 5-17y. In the second

sensitivity analysis we assumed that there was no RSV-attributable antibiotic prescribing for

those aged 18+ (**Table 3**). We calculated the results stratified by the same age groups as our base

case analysis, weighting by 2019 Scottish age group population sizes, and generated 1,000

simulations as per the base case analysis.

Impact of averted prescribing

We first converted the averted number of antibiotic courses to averted defined daily doses

(DDD) (assumed to be seven per antibiotic course (12)). We then used a previously published

statistical model to calculate the population impact of the averted DDD on resistant infections,

and calculated the health gain from these averted resistant infections in terms of the averted

deaths, and the Disability-Adjusted Life Years gained (13,14). We then calculated the averted

cost of these drug resistant infections (in 2020 GBP) by multiplying the number of averted drug

resistant infections by the 2020 cost of a drug resistant infection. This cost was assumed to be

$1415 in 2015 USD (15), deflated to 2014 prices, before converting to 2014 GBP using

equivalent health purchasing power (16), then inflated to 2020 prices at a rate of 2.3% per year

(17) giving a price of £586.83 per drug resistant infection.

Code and analysis

We conducted our analysis using R (18), plotted our results using ggplot2, and all code is

available at github.com/katiito/rsvvaccines_amr.

Results

Our search found 285 articles, 57 of which were excluded after title and abstract screening. After

full text review, ten articles met our inclusion criteria (**Table 1**). Only one of these studies

142 evaluated the impact of RSV infection on antibiotic use in a low income setting (19), with the

143 others conducted in the US and Europe. Studies covered a range of ages, with estimates from

144 either children, all household members, or the elderly. Studies provided estimates of one or more

145 of the following: the rate of RSV-associated antibiotic use in population, the rate or proportion of

146 antibiotic use per RSV episode, and the rate or proportion of RSV episodes per antibiotic course.

147 Studies were either retrospective or prospective cohorts or statistical attributable models.

148 Differences in study design and reporting prevent straightforward comparisons between the

149 estimates. For our analysis, we use the two study estimates that are both in the UK, and because

150 of their similar study design, study population and age-stratification, lead to more comparable

151 estimates.

153 We first assessed the impact of RSV immunisation strategies on primary care visits. Our model

154 found that only four intervention strategies were able to reduce primary care visits by more than

155 5% in non-targeted age groups through herd protection: seasonal administration of monoclonal

156 antibodies to <6 months (MAB ALL S+), seasonal (VAC INF S) or year-round (VAC INF A)

157 administration of infant vaccination, and seasonal administration of vaccine to 5-14y (VAC 5-14

158 S). Conversely, many strategies did not reduce GP visits by 5% within the target age group

159 (**Table 4**).

161 There was a substantial difference in the annual number of antibiotic courses averted across both

162 age group and intervention strategy. For infants <6 months, the largest number of courses averted

163 were for mAb strategies administered to all infants, and for any of the infant or maternal vaccine

164 strategies. Similarly, those aged 6-23 months benefitted from mAb or infant vaccine strategies.

For older children, only vaccines that targeted their age group led to substantial benefits in

annual averted antibiotic courses (**Figure 1**).

The strategies that performed best at reducing antibiotic prescribing across the whole population

were, in decreasing order: 5-14y vaccination (a reduction of 10.9, 95% CI: 8.0-14.2 antibiotic

courses per 10,000 person years; VAC 5-14 S), 2-4y vaccination (6.6, 95% CI: 5.0-8.3; VAC 2-4

S), seasonal monoclonal antibody administration to all infants under 6 months (6.0, 95% CI:4.4-

7.5; MAB ALL S+), then 5-9y vaccination (5.0, 95% CI: 3.6-6.7; VAC 5-9 S), then year-round

infant vaccine (4.6, 95% CI: 3.8-5.5; VAC INF A). The remaining strategies averted on average

fewer than 3 antibiotic courses per 10,000 person years across all simulations (**Figure 1**). The

best performing strategy of seasonal child and adolescent vaccination (VAC 5-14 S) averted

0.23% (95% CI: 0.16-0.29%) of the total antibiotic prescriptions (for any indication or aetiology)

recorded in 2018. Monoclonal antibody administration to high risk infants most efficiently

reduced antibiotic use per intervention course, reducing the number of antibiotic courses per

person year by 2.6 (95% CI: 1.9-3.3) per 1,000 mAb doses (**Figure 1**).

We calculated that seasonally vaccinating those aged 5-14 years (VAC 5-14 S) would lead to an

annual gain of 128 (95% CI: 91-165) DALYs due to averting drug-resistant bacterial infections.

This annual gain in DALYs is attributable to 86 (95% CI:61-111) infections and 4 (95% CI:3-6)

deaths caused by drug-resistant bacteria (**Figure 2**). The annual averted cost of these drug

resistant cases, which would be in addition to averted costs due to RSV disease, is £51,000 (95%

CI:36,000-65,000) in 2020.

The sensitivity analyses projected less impact of RSV vaccines on antibiotic use. Under the first

sensitivity analysis, the 5-14y vaccine strategy (VAC 5-14 S) averts 5.8 (95% CI: 3.1-9.5)

antibiotic courses per 10,000 person years, equivalent to around 0.1% (95% CI: 0.06-0.2%) of all

prescriptions in 2018 (**Figure S1, S2**). Under the alternative assumptions in the presence of no

RSV-attributable prescribing over the age of 17 years, we found that toddler vaccination and

child/adolescent vaccination were equally impactful in averting antibiotic courses. For

comparison, under these most conservative assumptions, the child and adolescent strategy averts

2.5 (95% CI: 1.4-4.0) antibiotic courses per 10,000 person years, leading to a total annual gain of

29 DALYs (95% CI: 17-46) (**Figure S3, S4**).

Discussion

Our study found that under the highest estimated RSV-attributable prescribing rates, the most impactful child and adolescent vaccination strategy was able to avert a quarter of a percent of the annual antibiotic prescriptions in England. This effect is limited due to a combination of factors: first, vaccination targeting the young will not substantially decrease the number of primary care visits across older age groups, so the average impact across the entire population is small. Second, antibiotic use attributable to RSV decreases with age, dropping from 20% for those under 6 months to 4% for ages 5-17 years. Finally, the assumed efficacy and uptake of the vaccine limit the total reduction in primary care visits.

Our analysis found that the combination of age-targeted RSV vaccination and age-specific variability in the RSV-associated antibiotic prescribing rates led to substantial differences in the potential reduction in antibiotic prescribing across age groups. For example, the most impactful strategy for the youngest age group, administering monoclonal antibodies to those under 6 months, would avert antibiotic prescriptions at a rate 30 times higher than is estimated in the entire population. Further, the size of the immunisation strategy largely predicts the total impact of averting antibiotic use, with the notable exception of vaccinating toddlers aged 2-4 years and monoclonal antibody administration of monoclonal antibodies to those aged less than 6 months. The impact of these two strategies across the entire population was relatively impactful due to both high coverage and efficiency.

Given increasing interest in the use of vaccines, including viral vaccines, to control antibiotic

resistance, it is advisable to consider averted resistance outcomes in the economic evaluation of

vaccines. However for RSV, our analysis suggests there would be a modest gain in DALYs

attributable to averted drug resistant infections. Specifically, even the most impactful programme

under the most optimistic scenario, a seasonal childhood vaccination for 5-14 year olds, would

save £51K and 128 DALYs in drug resistant outcomes. Conversely, if this programme were to

be administered at £20 per vaccine course, it would cost over £81 million and need to gain 4,100

quality-adjusted life years (QALYs) to be cost-effective in England (assuming a willingness-to-

pay of £20,000/QALY). Therefore, the main benefit of RSV vaccination is likely to be in

averting RSV itself, rather than averting antibiotic resistance due to by-stander selection. As

noted previously (13), the analysis calculating antibiotic resistant outcomes assumes a

counterfactual of no infection. Any deviation from this assumption would further reduce the

impact of RSV vaccination on resistant outcomes (20).

Our results suggest that with a fixed uptake and efficacy of a vaccine, the impact of an RSV

immunisation strategy on antibiotic prescribing is largely driven by the rate of antibiotic use

attributable to RSV. For countries where antibiotic use due to RSV is high, the benefits of an

RSV vaccine programme could be much larger and conceivably alter the cost-effectiveness of

vaccination strategies. Indeed, a study in Maela, on the Thailand-Myanmar border found that

young children who presented with antibiotic-indicated pneumonia who were later confirmed as

RSV-infected did so at over twice the rate (240 courses given per 1000 children) (19) as children

of the same age prescribed antibiotics in primary care attributable to RSV in the UK (110 courses

given per 1000 children) (6). As the clinical presentation and antibiotic prescribing was not

comparable between the two studies, it is likely that a vaccine targeted at children in Maela

would have more than double the impact on reducing antibiotic use compared with children in

the UK. Moreover, it is not only the rate of RSV-associated symptoms that determines the effect

of an RSV vaccine on antibiotics, but the magnitude of total antibiotic use. For settings where

over-the-counter, unregulated antibiotic use comprise the majority of drug consumption – and

where, as a consequence, multidrug resistance will be higher – the benefits of RSV vaccines on

controlling drug resistance will likely be substantially larger.

Contributors

KEA conceived the study. KEA did the literature review and data analysis. KEA, DH, MJ, and

NGD interpreted the data. DH reviewed the code. KEA wrote the manuscript, which was

critically revised by DH, MJ, and NGD.

Funding

N.G.D. and M.J. were funded by the National Institute for Health Research Health Protection

Research Unit (NIHR HPRU) in Immunisation (HPRU-2019-NIHR200929) at the London

School of Hygiene and Tropical Medicine and M.J. was funded by the NIHR HPRU in

Modelling & Health Economics (HPRU-2019-NIHR200908) at Imperial College and the London

School of Hygiene and Tropical Medicine, both in partnership with the UK Health Security

Agency. The views expressed are those of the authors and not necessarily those of the NHS,

National Institute for Health Research, Department of Health or the UK Health Security Agency.

About the authors

Dr Atkins is a Chancellor's Fellow and Associate Professor whose work focuses on the

epidemiology of antibiotic resistance and HIV.

Transparency declarations

Nothing to declare.

272
273

274
275

278 **Table 1:** Literature review of RSV-associated antibiotic use in the community, outpatient visits, and long-term care facilities.

Study first author (year) (reference)	Country	Population	Study Type	Reported Outcome					
				Rate of RSV-associated abx use in population		Abx use per RSV episode		RSV episodes per abx course	
				Number of abx courses in vc RSV cases / 1000 py	*Number of primary care abx courses attributable to RSV / 1000py*	*Number of abx courses / RSV-related primary care visit*	*% of vc RSV cases receiving abx courses*	*% of abx courses in study population with vc RSV*	*% of abx courses in background population attributable to RSV*
Ellis (2003) (21)	United States	Nursing home residents over 65 years presenting with fever or respiratory symptoms	Retrospective cohort	62.4 (43.4–81.3) (Not high risk) 75.6 (58.7–92.5) High risk)				3.3 (Not high risk) 2.8 (High risk)	
Caram (2009) (22)	United States	LTCF for older adults presenting with RTI	Prospective cohort				29% (2/7)		
Turner (2012) (19)	Thailand (Maela)	Children (birth to 2y) in refugee population presenting with	Prospective cohort	240 (95% CI 220–260)					

		pneumonia							
Meijboom (2013) (23)	Netherlands	Over 60y	Statistical analysis			0.75*			
Taylor (2016) (6)	United Kingdom	Children with recorded primary care antibiotic prescription	Statistical analysis of EHR		<6mo: 83.28 (55.47–102.65) 6-23mo: 119.16 (84.32–136.84) 2-4y: 74.95 (50.84–90.51) 5-17y: 10.91 (6.86–14.27)				<6mo: 19.7 6-23mo: 14.6 2-4y: 13.6 5-17y: 4.2†
Heikkinen (2017) (24)	Finland	Healthy children prospective study attending outpatient clinic (0-13y)	Prospective cohort				All: 54 (162/298) <1y: 91 (10/11) 1y: 63 (30/48) 2y: 64 (58/90) 3-6y: 48 (59/124) 7-13y:20 (5/25) **		
Smithgall (2020) (25)	United States	Household study of all ages presenting with ARI symptoms	Prospective household				24 (16/66)		
Toivonen (2020) (26)	Finland	Healthy children 0-2y presenting with ARI	Prospective birth cohort				35 (102/289) **		

Korsten (2021) (27)	Belgium/United Kingdom/Netherlands	Healthy community people 60+ years presenting with ARI	Prospective cohort				2/36 (6%)		
Fitzpatrick (2021) (7)	United Kingdom	Children under 5y with recorded community antibiotic prescribing	Statistical analysis of EHR						All: 6.92 (5.59, 8.25) <1y: 5.16 (3.91, 6.41) 1-4y: 5.80 (4.55, 7.04)

279   abx: antibiotic; py: person years; vc: virologically confirmed; EHR: electronic health records; ARI: acute respiratory infection

280   *calculated using excess antibiotic prescriptions and GP visits from the RSV season in the Netherlands (28)

281   **very low rate of hospitalizations so assumption that all antibiotic are community-prescribed

282   † from antibiotic prescriptions limited to those used against respiratory disease: broad spectrum penicillins, macrolides, tetracyclines

288 **Table 2**: Intervention assumptions. Each intervention was compared to status quo Palivizumab

289 administered seasonally to very high risk infants (9).

Intervention	Value	Notes
Monoclonal antibodies		
Delay between administration and protection (days)	None	(29)
Average period of protection (days)	275	(29)
Efficacy against symptomatic infection (%)	70.1 (52.3–81.0)	(30)
Uptake (%)	90%	Same as Palivizumab (9)
*Maternal vaccination**		
Average period of protection (days)	133.5 (119.6–146.1)	Same as estimated maternal immunity
Efficacy against symptomatic infection (%)	41.4 (4.1–64.2)	From Novavax Resvax trial (31)
Uptake (%)	60	Same as Tdap uptake in 3rd trimester (9)
Childhood / adolescent vaccination		

Delay between administration and protection (days)	11.4 (2.8–22.1)	Same as influenza antibody delay (32)
Average period of protection (days)	358.9 (350.7–364.7)	Assumed to be same as natural immunity (9)
Efficacy against any infection (%)	9-56%**	Assumed to be same as natural immunity (9)
Uptake (%)	90 (<1y) 45 (2-4y) 60 (5+y)	Assumed to be same as primary series (<1y) or LAIV (2+y) (9)

LAIV: live attenuated influenza vaccine

* Effect on infant; effect on mother assumed the same as childhood vaccination

** Mean efficacy shown for illustrative purposes. Vaccination provides temporary protection against any disease,

before individual move into a reduced susceptibility state, consistent with natural exposure. The efficacy is not used

explicitly in the model, but a range can be calculated as $1 - [s + (1-s)r_i]$ for i=1,2,3, where s is the probability of

seroconversion after vaccination (s = 83.0% (75.0–88.0%)) and r_i is the risk of infection after i previous exposures

relative to after i-1 previous exposures (r_1 = 0.89 (0.85–0.93), r_2 = 0.81 (0.74–0.85), r_3 = 0.33 (0.31–0.37)).

Table 3: RSV-attributable antibiotic prescribing assumptions

	RSV-attributable antibiotic prescribing (courses per 100,000 person years, 95% CI)				
	0-5mo	**6-23mo**	**2-4y**	**5-17y**	**18+y**
Base case*					
Analysis A	8328 (5547-10265)	11916 (8432-13684)	7495 (5084-9051)	1091 (686-1427)	1091 (686-1427)
Sensitivity analysis**					

Analysis B	2758 (2086-3428)	3350 (2821-3918)	3635 (2876-4425)	559 (306-912)	559 (306-912)
Analysis C	2758 (2086-3428)	3350 (2821-3918)	3635 (2876-4425)	559 (306-912)	0 (0-0)

299 * assumption 18+y the same as 5-17y

300 **underlying rates <1 year (2,770, 95% CI: 2078, 3409);1-4 years (3,645 95% CI: 2,891, 4,400);

301 ratio of 5-17y to 2-4y same as base case values.

303 **Table 4:** Predicted reduction in RSV-attributable primary care visits in England

Intervention*	Vaccine/ mAb courses (per year)	Proportion of RSV-attributable primary care visits averted** (95% credible interval)				
		0-5mo	6-23mo	2-4y	5-17y	18+y
Monoclonal antibodies						
MAB VHR S Seasonal Very high risk <8mo	2,218	0.064 (0.0094 – 0.12)	0.037 (-0.0033 – 0.076)	0.013 (-0.0031 – 0.029)	0.00011 (-4.6e-05 – 0.00041)	0.00023 (7.2e-05 – 4e-04)
MAB HR S Seasonal Very high risk <8mo High risk at birth	11,679	1.4 (1 – 1.6)	0.73 (0.55 – 0.87)	0.28 (0.2 – 0.33)	0.0016 (0.00038 – 0.0028)	0.00096 (7.6e-05 – 0.002)
MAB HR S+ Seasonal Very high risk <8mo High risk <6 mo	22,907	1.9 (1.5 – 2.3)	1.8 (1.4 – 2.1)	0.72 (0.55 – 0.84)	0.0088 (0.0043 – 0.013)	-0.004 (-0.0068 – -0.0016)
MAB ALL S Seasonal All infants at birth	252,581	27 (21 – 32)	4.4 (3.4 – 5.1)	1.6 (1.2 – 1.8)	0.037 (0.024 – 0.053)	0.17 (0.13 – 0.22)
MAB ALL S+ Seasonal	547,818	38 (30 – 44)	16 (12 – 19)	3.9 (3 – 4.5)	0.11 (0.077 – 0.15)	0.35 (0.24 – 0.44)

All infants <6 mo						
Maternal vaccination						
MAT S Seasonal 28-32wga pregnancy	165,257	7.7 (3.6 – 12)	-0.47 (-0.83 – -0.12)	-0.15 (-0.24 – -0.055)	0.055 (0.037 – 0.075)	0.28 (0.23 – 0.32)
MAT A Year round 28-32wga pregnancy	406,442	12 (6.1 – 17)	-0.11 (-0.42 – 0.14)	-0.26 (-0.42 – -0.11)	0.16 (0.12 – 0.21)	0.59 (0.51 – 0.68)
Childhood vaccination						
VAC INF S Seasonal Infants 2 months	251,162	24 (21 – 25)	5.5 (4.9 – 6.1)	0.6 (0.51 – 0.69)	-0.0034 (-0.017– 0.0079)	0.27 (0.2 – 0.34)
VAC INF A Year round Infants 2 months	617,724	34 (30 – 36)	13 (11 – 14)	1.3 (1.1 – 1.5)	0.006 (-0.026 –0.028)	0.48 (0.35 – 0.63)
VAC 2-4 S Seasonal Toddlers 2-4 years	917,008	0.91 (0.74 – 1.1)	0.55 (0.44 – 0.71)	21 (19 – 22)	0.6 (0.43 – 0.79)	1.2 (1 – 1.5)
Seasonal Children 5-9 years VAC 5-9 S	2,046,820	-0.32 (-0.43 – -0.14)	0.19 (0.11 – 0.34)	1.3 (1 – 1.6)	13 (8.2 – 16)	3.1 (2.6 – 3.7)
VAC 5-14 S Seasonal Children 5-14 years	4,093,640	-0.96 (-1.2 – -0.6)	-0.017 (-0.18 – 0.25)	2 (1.5 – 2.5)	26 (23 – 28)	7.5 (6.1 – 8.9)

304 * Monoclonal antibody programmes replace current Palivizumab programme, all other programmes are in addition.

305 **Proportion averted relative to the status quo strategy of Palivizumab seasonally administered to very high risk

306 infants <1mo

307 mAb: monoclonal antibodies; wga: weeks gestational age

Figure 1: Averted antibiotic courses for each of the monoclonal antibodies (MAB), maternal

vaccination (MAT) and age-targeted vaccination (VAC) interventions under base case

assumptions (upper panel). Efficiency of each of the strategies at averting antibiotic courses

(lower panel) under base case assumptions. Note the different y-axis scales.

Figure 2: Population impact of the reduction in antibiotic prescribing for each of the monoclonal

antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC)

interventions under base case assumptions.

References

References

1. Review on Antimicrobial Resistance. Tackling Drug-resistant Infections Globally: Final
Report and Recommendations. 2016. 80 p.

2. Atkins KE, Lipsitch M. Can antibiotic resistance be reduced by vaccinating against
respiratory disease? Lancet Respir Med. 2018 Nov;6(11):820–1.

3. Buckley BS, Henschke N, Bergman H, Skidmore B, Klemm EJ, Villanueva G, et al. Impact
of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol
Infect. 2019 Oct;25(10):1213–25.

4. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global,
regional, and national disease burden estimates of acute lower respiratory infections due to
respiratory syncytial virus in young children in 2015: a systematic review and modelling
study. Lancet. 2017 Sep 2;390(10098):946–58.

5. Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory
syncytial virus disease and potential effect of different immunisation strategies: a modelling
and cost-effectiveness analysis for England. Lancet Public Health. 2017 Aug;2(8):e367–74.

6. Taylor S, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling
estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ
Open. 2016 Jun 2;6(6):e009337.

7. Fitzpatrick T, Malcolm W, McMenamin J, Reynolds A, Guttmann A, Hardelid P.
Community-Based Antibiotic Prescribing Attributable to Respiratory Syncytial Virus and
Other Common Respiratory Viruses in Young Children: A Population-Based Time-series
Study of Scottish Children. Clin Infect Dis. 2021 Jun 15;72(12):2144–53.

8. RSV Vaccine and mAb Snapshot [Internet]. [cited 2021 Oct 18]. Available from:
https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/

9. Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next
generation of RSV intervention strategies: a mathematical modelling study and cost-
effectiveness analysis. BMC Med. 2020 Nov 18;18(1):348.

10. RSV Vaccine and mAb Snapshot [Internet]. [cited 2021 Oct 18]. Available from:
https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/

11. [No title] [Internet]. [cited 2021 Oct 29]. Available from:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat
a/file/458469/Green_Book_Chapter_27a_v2_0W.PDF

12. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration
of antibiotic treatment for common infections in English primary care: cross sectional
analysis and comparison with guidelines. BMJ. 2019 Feb 27;364:l440.

13.   Chae C, Davies NG, Jit M, Atkins KE. Effect of Pediatric Influenza Vaccination on
Antibiotic Resistance, England and Wales. Emerg Infect Dis. 2020 Jan;26(1):138–42.

14.   Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al.
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-
resistant bacteria in the EU and the European Economic Area in 2015: a population-level
modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56–66.

15.   Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating
the economic cost of antimicrobial resistance per antibiotic consumed to inform the
evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018 Aug
9;7:98.

16.   Website [Internet]. Available from: https://www.oecd.org/health/health-systems/ #
International-Comparisons-of-Health-Prices-and-Volumes-New-Findings.pdf

17.   Inflation calculator [Internet]. [cited 2021 Oct 28]. Available from:
https://www.bankofengland.co.uk/monetary-policy/inflation/inflation-calculator

18.   The R Project for Statistical Computing [Internet]. [cited 2021 Sep 28]. Available from:
https://www.R-project.org

19.   Turner C, Turner P, Cararra V, Lwe NE, Watthanaworawit W, Day NP, et al. A High
Burden of Respiratory Syncytial Virus Associated Pneumonia in Children Less than Two
Years of Age in a South East Asian Refugee Population [Internet]. Vol. 7, PLoS ONE.
2012. p. e50100. Available from: http://dx.doi.org/10.1371/journal.pone.0050100

20.   de Kraker MEA, Lipsitch M. Burden of Antimicrobial Resistance: Compared to What?
Epidemiol Rev [Internet]. 2021 Mar 12; Available from:
http://dx.doi.org/10.1093/epirev/mxab001

21.   Ellis SE, Coffey CS, Mitchel EF Jr, Dittus RS, Griffin MR. Influenza- and respiratory
syncytial virus-associated morbidity and mortality in the nursing home population. J Am
Geriatr Soc. 2003 Jun;51(6):761–7.

22.   Caram LB, Brett Caram L, Chen J, William Taggart E, Hillyard DR, She R, et al.
Respiratory Syncytial Virus Outbreak in a Long-Term Care Facility Detected Using
Reverse Transcriptase Polymerase Chain Reaction: An Argument for Real-Time Detection
Methods [Internet]. Vol. 57, Journal of the American Geriatrics Society. 2009. p. 482–5.
Available from: http://dx.doi.org/10.1111/j.1532-5415.2008.02153.x

23.   Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV vaccine in development:
assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. 2013
Dec 16;31(52):6254–60.

24.   Heikkinen T, Ojala E, Waris M. Clinical and Socioeconomic Burden of Respiratory
Syncytial Virus Infection in Children. J Infect Dis. 2017 Jan 1;215(1):17–23.

25.   Smithgall M, Maykowski P, Zachariah P, Oberhardt M, Vargas CY, Reed C, et al.
397   Epidemiology, clinical features, and resource utilization associated with respiratory
398   syncytial virus in the community and hospital. Influenza Other Respi Viruses. 2020
399   May;14(3):247–56.

400   26.   Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Mertsola J, Waris M, et
401   al. Respiratory syncytial virus infections in children 0-24 months of age in the community. J
402   Infect. 2020 Jan;80(1):69–75.

403   27.   Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden of
404   respiratory syncytial virus infection in community-dwelling older adults in Europe
405   (RESCEU): an international prospective cohort study. Eur Respir J [Internet]. 2021
406   Apr;57(4). Available from: http://dx.doi.org/10.1183/13993003.02688-2020

407   28.   Assink MDM, Kiewiet JP, Rozenbaum MH, Van den Berg PB, Hak E, Buskens EJ, et al.
408   Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential
409   implications for extended influenza vaccination. Vaccine. 2009 Feb 11;27(7):1119–26.

410   29.   Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, et al. Safety,
411   Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose
412   Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a
413   Single Dose to Healthy Preterm Infants. Pediatr Infect Dis J. 2018 Sep;37(9):886–92.

414   30.   Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-Dose
415   Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul
416   30;383(5):415–25.

417   31.   Novavax, Inc. Novavax Announces Topline Results from Phase 3 PrepareTM Trial of
418   ResVaxTM for Prevention of RSV Disease in Infants via Maternal Immunization [Internet].
419   Novavax, Inc. 2019 [cited 2021 Oct 14]. Available from:
420   https://www.globenewswire.com/news-release/2019/02/28/1744163/14446/en/Novavax-
421   Announces-Topline-Results-from-Phase-3-PrepareTM-Trial-of-ResVax-for-Prevention-of-
422   RSV-Disease-in-Infants-via-Maternal-Immunization.html

423   32.   Baguelin M, Hoschler K, Stanford E, Waight P, Hardelid P, Andrews N, et al. Age-specific
424   incidence of A/H1N1 2009 influenza infection in England from sequential antibody
425   prevalence data using likelihood-based estimation. PLoS One. 2011 Feb 23;6(2):e17074.

426
427
428

Sensitivity Analysis Results

Figure S1: Sensitivity analysis (analysis B) of averted antibiotic courses for each of the monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination (VAC) interventions (upper panel), and efficiency of each of the strategies at averting antibiotic courses (lower panel). Note the different y-axis scales.

440
441 **Figure S2:** Sensitivity analysis (analysis B) for the population impact of the reduction in
442 antibiotic prescribing for each of the monoclonal antibodies (MAB), maternal vaccination
443 (MAT) and age-targeted vaccination (VAC) interventions.
444
445

447 **Figure S3:** Sensitivity analysis (analysis C) of averted antibiotic courses for each of the

448 monoclonal antibodies (MAB), maternal vaccination (MAT) and age-targeted vaccination

449 (VAC) interventions (upper panel), and efficiency of each of the strategies at averting antibiotic

450 courses (lower panel). Note the different y-axis scales.

452
453
454 **Figure S4:** Sensitivity analysis (analysis C) for the population impact of the reduction in
455 antibiotic prescribing for each of the monoclonal antibodies (MAB), maternal vaccination
456 (MAT) and age-targeted vaccination (VAC) interventions.
457